Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for Bexobrutideg (NX-5948) in Cancer, B-cell malignancies. The expected timing is based on the latest available company guidance and may change.
07/09/26:- EHA CLL data updated; further NX-5948-301 updates expected in 2026.
Verification
Confirm timing and program details against the company announcement or filing.